News Pfizer looks to M&A after results disappointment Pfizer is looking to deals to keep investors onside after a disappointing set of Q4 results.
News BMS suffers further setback in lung cancer No fast approval for immunotherapy combo in first line use.
News AZ looks for advantage over Merck in lung cancer trial AZ rejigs endpoints in key trial of durvalumab
News Novartis, BMS, Janssen unveil R&D deals Companies announce eye-catching R&D plans ahead of conference.
News BMS and PsiOxus to collaborate on cancer-targeting armed vir... BMS to pay up to $936m for NG-348.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.